Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Hepatocellular Carcinoma
- Advanced Solid Tumor
- Cervical Cancer
- Colorectal Cancer
- EGFR Positive Solid Tumor
- Gastric Cancer
- Head and Neck Cancer
- NSCLC
- Microsatellite Instability
- Renal Cell Carcinoma
- Urothelial Carcinoma
- HER2 Positive Breast Cancer
- Lymphoma
- Melanoma
- Squamous Cell Carcinoma
- Merkel Cell Carcinoma
- Small Cell Lung Cancer
- Pancreas Cancer
- Type
- Observational
- Design
- Observational Model: Case-OnlyTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This is a multicenter, non-interventional, observation study designed to provide long-term safety and efficacy data on subjects who have participated in a prior Fate Therapeutics interventional study of FT500 cellular immunotherapy. Subjects will be contacted every six months (± one month), beginnin...
This is a multicenter, non-interventional, observation study designed to provide long-term safety and efficacy data on subjects who have participated in a prior Fate Therapeutics interventional study of FT500 cellular immunotherapy. Subjects will be contacted every six months (± one month), beginning six months after subject completion or withdrawal from the FT500-101 study.
Tracking Information
- NCT #
- NCT04106167
- Collaborators
- Not Provided
- Investigators
- Study Director: Wayne Chu, MD Fate Therapeutics
Get Well Soon